Evaluation of 21st-century risks of smallpox vaccination and policy options.
about
Frequency of adverse events after vaccination with different vaccinia strainsVaccines for preventing smallpoxSmallpox vaccine: the good, the bad, and the ugly.Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968Comparison of smallpox outbreak control strategies using a spatial metapopulation model.New generation smallpox vaccines: a review of preclinical and clinical data.Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.Risks and benefits of preexposure and postexposure smallpox vaccination.Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Smallpox: clinical features, prevention, and management.Pathogen-specific recombinant human polyclonal antibodies: biodefence applications.Failure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after.Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Laboratory confirmation of generalized vaccinia following smallpox vaccinationRapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeuticsInhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells.
P2860
Q21092385-1E07E26C-6AA3-48C9-9B30-0481F2BEA7A5Q24244234-9777CCB7-2CF6-4190-8831-63D452F1C951Q24520563-53D3D746-7B77-42EC-BC20-AF7750FA3DC6Q24799168-7FBEAB55-9472-4EA3-9CB4-4E22685B5591Q30230157-FBADA110-2993-46CD-BD9A-1AA5514FEDC5Q31147081-A0E529D9-07CE-4E49-8221-DC75CB91F11FQ33780579-270097C2-8906-4236-9790-3F4A257F7085Q34560088-3ED3ED5E-D0BC-4236-8ADA-D1B39F6CDB8BQ34982651-EBD41B60-2064-44B7-A6F3-0F5EB5533D82Q35202813-B770C60B-83BD-4A64-A3BD-31B91A00F7AAQ35571248-B4985C69-1C74-4FAC-A9DE-F62E2124740AQ35644860-9287805C-C605-488E-9E1B-1723650FED4BQ35684876-85CBB336-2346-4E20-BA28-FBAE4B43C82EQ35805278-03CBD07F-3AC7-4CBE-856B-CDEA00F71D6CQ35844057-58279B31-F254-40A9-9094-04D25AA6B47EQ36391900-553BE9C6-6CA6-420B-B2B5-34D785090BD7Q36599418-14A390C4-5BF8-410A-9F79-3416BC940936Q36808703-B16FD5AC-56EF-4650-AD9C-CCC89F10B567Q37125302-AB75E52C-CC4C-4C49-82B7-1B30EEFE01ECQ37169163-79EAB186-ABAD-484F-B545-BE003D861C13Q37191938-D2BEF78E-6134-44B3-9CCA-43BCAF156CD3Q37734396-373CA101-831F-48A7-9C44-CEB8BD537A03Q42633733-835C8F33-4AFC-41AA-B15E-17F629E6D9DDQ45406264-08F66215-3704-43AD-96F7-D1AC386E9965
P2860
Evaluation of 21st-century risks of smallpox vaccination and policy options.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@ast
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@en
type
label
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@ast
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@en
prefLabel
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@ast
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@en
P1476
Evaluation of 21st-century risks of smallpox vaccination and policy options.
@en
P2093
J Michael Lane
Joel Goldstein
P304
P356
10.7326/0003-4819-138-6-200303180-00014
P407
P577
2003-03-01T00:00:00Z